前列腺癌雄激素治疗的演变与现状

参考文献：

[1] 前列腺癌诊断治疗指南（中国泌尿外科和男科疾病诊断治疗指南2022版）

[2] Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy [published correction appears in N Engl J Med. 2013 Feb 7;368(6):584]. N Engl J Med. 2013;368(2):138-148. doi:10.1056/NEJMoa1209096

[3] Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424-433. doi:10.1056/NEJMoa1405095

[4] 马维维,韦煜,朱耀,雄激素受体驱动前列腺癌去势抵抗的研究进展.中华泌尿外科杂志,2023，44(09) : 713-716. DOI: 10.3760/cma.j.cn112330-20220719-00424

[5] 张君席,刘振湘,恩杂鲁胺和阿比特龙耐药机制及其耐药后新型临床治疗方案的研究进展.国际泌尿系统杂志,2019，39(2) : 363-363. DOI: 10.3760/cma.j.issn.1673-4416.2019.02.053

[6] Hou Z, Huang S, Mei Z, et al. Inhibiting 3βHSD1 to eliminate the oncogenic effects of progesterone in prostate cancer. Cell Rep Med. 2022;3(3):100561. Published 2022 Mar 15. doi:10.1016/j.xcrm.2022.100561